E Fund Management (HK)
SMMT icon

E Fund Management (HK)’s Summit Therapeutics SMMT Stock Holding History

E Fund Management (HK)’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$19.3K Sell
1,139
-195
-15% -$2.92K ﹤0.01% 397
2026
Q2 		$19.4K Buy
1,334
+380
+40% +$6.74K 0.01% 322
2026
Q1 		$18.1K Buy
+954
New +$15.4K 0.01% 214

Other funds holding SMMT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return

E Fund Management (HK)'s SMMT Position: Q3 2026 in Review

E Fund Management (HK) reduced its Summit Therapeutics (SMMT) stake by 15% in Q3 2026, selling an estimated $2.92K and leaving 1,139 shares worth $19.3K. The position accounts for ﹤0.01% of the portfolio, ranked #397.

E Fund Management (HK) first reported a position in SMMT in Q1 2026 and has held it in 3 quarters since. The position peaked at $19.4K in Q2 2026. 172 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • E Fund Management (HK) held 1,139 shares of Summit Therapeutics worth $19.3K as of Q3 2026.
  • E Fund Management (HK) sold 195 Summit Therapeutics shares in Q3 2026, an estimated $2.92K.
  • Summit Therapeutics made up ﹤0.01% of E Fund Management (HK)'s portfolio in Q3 2026, its #397 holding.
  • E Fund Management (HK) first reported a position in Summit Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • E Fund Management (HK)'s Summit Therapeutics position peaked at $19.4K in Q2 2026.
  • 172 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on E Fund Management (HK)'s 13F filing for Q3 2026, filed 12 Nov 2026.